Racivir

Racivir
Clinical data
Routes of; administration	Investigational
ATC code	none;
Identifiers
	IUPAC name 4-amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one;
CAS Number	137530-41-7;
PubChem CID	454858;
ChemSpider	400521;
NIAID ChemDB	005245;
CompTox Dashboard (EPA)	DTXSID701288260 ;
Chemical and physical data
Formula	C8H10FN3O3S
Molar mass	247.25 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1c(c(nc(=O)n1[C@H]2CS[C@H](O2)CO)N)F;
	InChI InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m1/s1; Key:XQSPYNMVSIKCOC-RITPCOANSA-N;

Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV.^[1] It is the enantiomer of emtricitabine, a widely used NRTI, meaning that the two compounds are mirror images of each other.

References

^ "Racivir". AIDSmeds.com. March 24, 2006. Archived from the original on 2014-01-02. Retrieved March 21, 2008.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.